Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF- June 20.03.2026 MJUN LN IE000CO3P697 150,002.00 USD 3,712,332.66 24.749  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - December 20.03.2026 QDEC.LN IE000GAKWFA7 450,002.00 USD 9,979,869.59 22.177  ...

STOCKHOLM--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Swedbank Robur Fonder AB (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be na...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 20.03.2026 FTEI.LN IE000TIZ5AP4 150,002.00 EUR 2,895,716.84 19.305  ...

BELMONT, Mass.--(BUSINESS WIRE)--Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced new clinical and neuroimaging data from an ongoing Phase 1b/2a study evaluating its autologous dopaminergic neuron replacement therapy for Parkinson’s disease. The study is being conducted in collaboration with expertise across Mass General Brigham led b...

LONDON--(BUSINESS WIRE)--Analysis of credit card data for January 2026 by global analytics software leader FICO (NYSE:FICO) shows the typical post-Christmas reduction in spending as customers prioritised payments after the festive break. However, with spending lower year-on-year and increases in missed payments, the financial pressures that were a feature of the UK economy for the majority of 2025 have continued into the new year, requiring risk and collections teams to remain vigilant. Highlig...

BELMONT, Mass.--(BUSINESS WIRE)--Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, today announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million. Investors included Neuro.VC, Byers Capital, and others. The company's initial program is a neu...

BOSTON & ZURICH--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance Launches Executive First D&O Liability Insurance Policies in Switzerland...

BOSTON und ZÜRICH--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) meldete heute die Einführung von zwei neuen Executive First D&O-Haftpflichtversicherungspolicen in der Schweiz: eine speziell für Gewerbe- und Industrieunternehmen, die andere für Finanzinstitute und Asset Manager. „Schweizer Unternehmen und deren Führungskräfte stehen vor einem zunehmend komplexen Risikoumfeld“, erklärte Christoph Kammermann, Head of Executive & Professional Lines, BHSI Schweiz. „Mit unse...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. Fo...